## Yoshihiko Kanno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8368992/publications.pdf

Version: 2024-02-01

144 papers 4,746 citations

31 h-index

147801

106344 65 g-index

152 all docs

152 docs citations

152 times ranked

4817 citing authors

#	Article	IF	Citations
1	Effectiveness of <scp>SARSâ€CoV</scp> â€2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. Therapeutic Apheresis and Dialysis, 2023, 27, 19-23.	0.9	12
2	Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis, 2022, 26, 1226-1234.	0.9	2
3	Blood pressure management in patients receiving renal replacement therapy. Hypertension Research, 2021, 44, 7-12.	2.7	2
4	Clinical significance of selenium deficiency in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2021, 54, 191-201.	0.1	0
5	Methods and Nutritional Interventions to Improve the Nutritional Status of Dialysis Patients in JAPAN—A Narrative Review. Nutrients, 2021, 13, 1390.	4.1	11
6	Structural changes in renal arterioles are closely associated with central hemodynamic parameters in patients with renal disease. Hypertension Research, 2021, 44, 1113-1121.	2.7	4
7	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	13.7	414
8	Glomerulonephritis Caused by <i>Bartonella</i> spp. Infective Endocarditis: The Difficulty and Importance of Differentiation from Anti-neutrophil Cytoplasmic Antibody-related Rapidly Progressive Glomerulonephritis. Internal Medicine, 2021, 60, 1899-1906.	0.7	6
9	Pump-Free Microfluidic Hemofiltration Device. Micromachines, 2021, 12, 992.	2.9	1
10	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	13.7	133
11	Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Renal Replacement Therapy, 2021, 7, 59.	0.7	34
12	Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Clinical and Experimental Nephrology, 2020, 24, 1-44.	1.6	31
13	Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Japanese Journal of Radiology, 2020, 38, 3-46.	2.4	9
14	Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. Clinical Drug Investigation, 2020, 40, 847-859.	2.2	16
15	Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. BMC Pharmacology & Employer (2019), 2020, 21, 60.	2.4	4
16	<scp>COVID</scp> â€19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic Apheresis and Dialysis, 2020, 24, 361-365.	0.9	53
17	A case of microscopic polyangiitis initially presented with erythema multiformeâ€ike skin eruptions. Journal of Cutaneous Immunology and Allergy, 2020, 3, 64-65.	0.3	0
18	We can have it all, but we just cannot have it all at once. Hypertension Research, 2020, 43, 835-836.	2.7	0

#	Article	IF	CITATIONS
19	Evaluation of the efficacy of granulocyte and monocyte adsorption apheresis on skin manifestation and joint symptoms of patients with pustulotic arthroâ€osteitis. Journal of Dermatology, 2019, 46, 144-148.	1.2	8
20	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	2.7	1,047
21	rAAV6-mediated miR-29b delivery suppresses renal fibrosis. Clinical and Experimental Nephrology, 2019, 23, 1345-1356.	1.6	19
22	A new nutritional risk index for predicting mortality in hemodialysis patients: Nationwide cohort study. PLoS ONE, 2019, 14, e0214524.	2.5	51
23	Identifying progressive CKD from healthy population using Bayesian network and artificial intelligence: A worksite-based cohort study. Scientific Reports, 2019, 9, 5082.	3.3	17
24	Comparison of accuracy between pre-hemodialysis and post-hemodialysis levels of nutritional factors for prediction of mortality in hemodialysis patients. Clinical Nutrition, 2019, 38, 383-388.	5.0	5
25	In vitro and in vivo tests of nanoporous membrane coated with biocompatible fluorine-doped diamond-like carbon for hemofiltration treatment. , 2018, , .		1
26	The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis. Hemodialysis International, 2018, 22, 388-393.	0.9	10
27	Refusal of blood transfusion by a hemodialysis patient with renal anemia for religious reasons. Nihon Toseki Igakkai Zasshi, 2018, 51, 409-413.	0.1	0
28	Letter regarding "Estimated aortic blood pressure based on radial artery tonometry underestimates directly measured aortic blood pressure in patients with advancing chronic kidney disease staging and increasing arterial stiffness― Kidney International, 2017, 91, 757.	5.2	0
29	Evaluation of biofouling in stainless microfluidic channels for implantable multilayered dialysis device. Japanese Journal of Applied Physics, 2017, 56, 06GN10.	1.5	4
30	L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients. Bioscience of Microbiota, Food and Health, 2017, 36, 11-16.	1.8	7
31	Fabrication and <i>in vitro</i> HF experiment for PES membrane coating f-DLC. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2017, 2017.8, PN-29.	0.0	0
32	<i>In vivo</i> evaluation of biofouling on titanium microfluidic channel for implantable artificial kidney. The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2017, 2017, 1A1-J06.	0.0	0
33	Appropriate dietary salt intake in patients receiving hemodialysis. Nihon Toseki Igakkai Zasshi, 2017, 50, 483-486.	0.1	0
34	Grounds for withdrawing dialysis treatment under criminal law. Nihon Toseki Igakkai Zasshi, 2016, 49, 561-569.	0.1	0
35	Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study. Endoscopy International Open, 2016, 04, E589-E596.	1.8	9
36	Clinical Practice of Two Measurements of Home Blood Pressure on Each Occasion in Patients with Chronic Kidney Disease. CardioRenal Medicine, 2016, 6, 8-15.	1.9	0

3

#	Article	IF	CITATIONS
37	Dietary intake in Japanese patients with kidney transplantation. Clinical and Experimental Nephrology, 2016, 20, 972-981.	1.6	6
38	Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study. Clinical and Experimental Nephrology, 2016, 20, 787-794.	1.6	12
39	Estimation of daily protein intake based on spot urine urea nitrogen concentration in chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 258-264.	1.6	13
40	Central blood pressure and chronic kidney disease. World Journal of Nephrology, 2016, 5, 90.	2.0	19
41	Water-Permeable Dialysis Membranes for Multi-Layered Microdialysis System. Frontiers in Bioengineering and Biotechnology, 2015, 3, 70.	4.1	27
42	Uric Acid Level Has a U-Shaped Association with Loss of Kidney Function in Healthy People: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0118031.	2.5	73
43	Association between visit-to-visit clinic blood pressure variability and home blood pressure variability in patients with chronic kidney disease. Renal Failure, 2015, 37, 446-451.	2.1	4
44	Evaluating central blood pressure in dialysis patients. Kidney International, 2015, 88, 193.	5.2	2
45	A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Journal of Diabetes Investigation, 2015, 6, 242-246.	2.4	157
46	Relationship between dietary protein intake and the changes in creatinine clearance and glomerular cross-sectional area in patients with IgA nephropathy. Clinical and Experimental Nephrology, 2015, 19, 661-668.	1.6	3
47	The effect of blood flow on heart stroke volume during a hemodialysis session. Nihon Toseki Igakkai Zasshi, 2015, 48, 239-242.	0.1	1
48	Acceptance of patients receiving peritoneal dialysis in geriatric health services facilities. Nihon Toseki lgakkai Zasshi, 2015, 48, 525-528.	0.1	0
49	30am2-PN-42 Biofouling of micro channel in implantable artificial kidney. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2015, 2015.7, _30am2-PN30am2-PN	0.0	0
50	1P1-L06 Evaluation of Implantable Micro Hemodialysis System. The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2015, 2015, _1P1-L06_11P1-L06_2.	0.0	0
51	Classification of Diabetic Nephropathy 2014. Nihon Toseki Igakkai Zasshi, 2014, 47, 415-419.	0.1	4
52	Factors affecting decline of residual renal function in maintenance hemodialysis patients. Nihon Toseki lgakkai Zasshi, 2014, 47, 629-636.	0.1	0
53	Calf circumference measurement for nutritional assessment in maintenance hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2014, 47, 679-684.	0.1	0
54	Malnutrition as cause of hypomagnesemia. Kidney International, 2014, 86, 856.	5.2	5

#	Article	IF	CITATIONS
55	Permeability and blood compatibility of nanoporous parylene filmâ€coated polyethersulfone membrane under longâ€term blood diffusion. Journal of Applied Polymer Science, 2014, 131, .	2.6	12
56	A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Diabetology International, 2014, 5, 207-211.	1.4	10
57	<i>Helicobacter cinaedi</i> infection in a polycystic kidney disease patient receiving hemodialysis. Nihon Toseki Igakkai Zasshi, 2014, 47, 501-506.	0.1	0
58	3P2-H07 Development of Implantable Micro Hemodialysis System(Nano/Micro Fluid System). The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2014, 2014, _3P2-H07_13P2-H07_2.	0.0	0
59	Electropolishing of Microchannels and its Application to Dialysis System. Procedia CIRP, 2013, 5, 164-168.	1.9	6
60	Antithrombogenicity of Fluorinated Diamond-Like Carbon Films Coated Nano Porous Polyethersulfone (PES) Membrane. Materials, 2013, 6, 4309-4323.	2.9	23
61	7AM2-C-8 Development of Implantable Micro Hemodialysis System. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2013, 2013.5, 253-254.	0.0	0
62	A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrology Dialysis Transplantation, 2012, 27, 1580-1584.	0.7	173
63	Anaphylactoid reaction to immunoadsorptive membrane in a patient with myasthenia gravis. CEN Case Reports, 2012, 1, 1-3.	0.9	0
64	Polyethersulfone Membrane Coated With Nanoporous Parylene for Ultrafiltration. Journal of Microelectromechanical Systems, 2012, 21, 1288-1290.	2.5	16
65	Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clinical and Experimental Nephrology, 2008, 12, 102-109.	1.6	52
66	Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial. American Journal of Kidney Diseases, 2008, 52, 501-506.	1.9	173
67	Viruses may trigger allopurinol hypersensitivity syndrome. CKJ: Clinical Kidney Journal, 2008, 1, 273-274.	2.9	2
68	Estrogen and Angiotensin II Interactions Determine Cardio-Renal Damage in Dahl Salt-Sensitive Rats with Heart Failure. American Journal of Nephrology, 2008, 28, 413-423.	3.1	18
69	Poly(ADP-Ribose) Polymerase-1 Enhances Transcription of the Profibrotic CCN2 Gene. Journal of the American Society of Nephrology: JASN, 2008, 19, 933-942.	6.1	27
70	Close association of vascular and valvular calcification and prognosis of patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2008, 24, 60-4.	0.1	2
71	Absence of Increased $\hat{l}\pm 1$ -Microglobulin in IgA Nephropathy Proteinuria. Molecular and Cellular Proteomics, 2007, 6, 738-744.	3.8	29
72	Elevation of plasma D-dimer is closely associated with venous thrombosis produced by double-lumen catheter in pre-dialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 1224-1227.	0.7	10

5

#	Article	IF	Citations
73	Diet Therapy in Patients Receiving Peritoneal Dialysis. , 2007, 155, 72-81.		1
74	Congenic Substitution Mapping for Intracellular Ca2+ in Spontaneously Hypertensive Rats. American Journal of Hypertension, 2007, 20, 172-176.	2.0	2
75	Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism: Clinical and Experimental, 2007, 56, 153-159.	3.4	38
76	Nutritional Assessment by a New Method for Patients with Renal Disease., 2007, 155, 29-39.		5
77	Effects of Endocrine Disrupting Substance on Estrogen Receptor Gene Transcription in Dialysis Patients. Therapeutic Apheresis and Dialysis, 2007, 11, 262-265.	0.9	26
78	Comparison and survival of patients receiving hemodialysis and peritoneal dialysis in a single center. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2007, 23, 144-9.	0.1	14
79	Residual renal function plays an important role in regulating parathyroid hormone in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2007, 23, 150-4.	0.1	2
80	Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner. American Journal of Pathology, 2006, 168, 737-747.	3.8	42
81	A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade. American Journal of Pathology, 2006, 169, 1577-1589.	3.8	41
82	Impact of Selectin Gene Polymorphisms on Rapid Progression to End-Stage Renal Disease in Patients with IgA Nephropathy. Internal Medicine, 2006, 45, 947-951.	0.7	17
83	A Fiveyear Comparison of the Renal Protective Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with NonDiabeticNephropathy. Internal Medicine, 2006, 45, 193-198.	0.7	27
84	Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 548-549.	0.7	25
85	Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2006, $1,730-737$ .	4.5	50
86	The efficacy of pre-washed rice (Musenmai) on diet therapy for hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2006, 39, 1187-1190.	0.1	2
87	Decline of Renal Function Is Associated with Proteinuria and Systolic Blood Pressure in the Morning in Diabetic Nephropathy. Clinical and Experimental Hypertension, 2005, 27, 129-138.	1.3	14
88	Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients. Hypertension Research, 2005, 28, 307-314.	2.7	77
89	An Angiotensin Receptor Blocker Reduces the Risk of Congestive Heart Failure in Elderly Hypertensive Patients with Renal Insufficiency. Hypertension Research, 2005, 28, 415-423.	2.7	27
90	Judicious Usage of Estrogen/Progesterone for Angiodysplasia. Artificial Organs, 2005, 29, 88-89.	1.9	5

#	Article	IF	CITATIONS
91	Low Doses of Losartan and Trandolapril Improve Arterial Stiffness in Hemodialysis Patients. American Journal of Kidney Diseases, 2005, 45, 866-874.	1.9	81
92	Connective tissue growth factor mediates the profibrotic effects of transforming growth factor- $\hat{l}^2$ produced by tubular epithelial cells in response to high glucose. Clinical and Experimental Nephrology, 2005, 9, 114-121.	1.6	44
93	Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis. Journal of the American Society of Nephrology: JASN, 2005, 16, 133-143.	6.1	170
94	Qualification of Arterial Stiffness as a Risk Factor to the Progression of Chronic Kidney Diseases. American Journal of Nephrology, 2005, 25, 417-424.	3.1	65
95	Cellular insulin resistance in Epstein-Barr virus-transformed lymphoblasts from young insulin-resistant Japanese men. Metabolism: Clinical and Experimental, 2005, 54, 370-375.	3.4	7
96	Comparison of changes in pulse wave velocity in patients on continuous ambulatory peritoneal dialysis and hemodialysis one year after introduction of dialysis therapy. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2005, 21, 139-45.	0.1	8
97	Clinical Strategy for the Treatment of Hypertension in Non-Diabetic and Diabetic Nephropathy in Japan. , 2004, 143, 145-158.		1
98	Bradykinin Decreases Plasminogen Activator Inhibitor-1 Expression and Facilitates Matrix Degradation in the Renal Tubulointerstitium under Angiotensin-Converting Enzyme Blockade. Journal of the American Society of Nephrology: JASN, 2004, 15, 2404-2413.	6.1	46
99	Angiotensin II Type 1 and Type 2 Receptors Reciprocally Modulate Pro-inflammatory/ Pro-Fibrotic Reactions in Activated Splenic Lymphocytes. American Journal of Nephrology, 2004, 24, 322-329.	3.1	7
100	Effects of Eplerenone on Heart and Kidney in Two-Kidney, One-Clip Rats. American Journal of Nephrology, 2004, 24, 54-60.	3.1	28
101	Ticlopidine induces lupus in a haemodialysis patient. Nephrology Dialysis Transplantation, 2004, 19, 2685-2686.	0.7	4
102	Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases, 2004, 43, 1056-1064.	1.9	184
103	Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications, 2004, 314, 403-408.	2.1	20
104	Angiotensin Receptor Antagonist Regresses Left Ventricular Hypertrophy Associated with Diabetic Nephropathy in Dialysis Patients. Journal of Cardiovascular Pharmacology, 2004, 43, 380-386.	1.9	41
105	Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2004, 20, 111-6.	0.1	15
106	An unusual form of crystal-forming chronic interstitial nephritis following long-term exposure to tosufloxacin tosilate. American Journal of Kidney Diseases, 2004, 44, 902-7.	1.9	3
107	Selection of hemoperfusion therapy for patients with septic shock on the basis of the primary disease. Journal of Artificial Organs, 2003, 6, 205-210.	0.9	2
108	A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clinical and Experimental Nephrology, 2003, 7, 48-51.	1.6	7

#	Article	IF	CITATIONS
109	Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney International, 2003, 64, 1722-1732.	5.2	38
110	Hepatocyte growth factor counteracts transforming growth factor $\hat{\mathbb{C}}^2$ 1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB Journal, 2003, 17, 268-270.	0.5	128
111	Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. Nephrology Dialysis Transplantation, 2003, 18, 2515-2523.	0.7	31
112	Direct Contact between Human Peripheral Blood Mononuclear Cells and Renal Fibroblasts Facilitates the Expression of Monocyte Chemoattractant Protein-1. American Journal of Nephrology, 2003, 23, 208-213.	3.1	17
113	A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 59-66.	0.1	39
114	Longitudinal changes of peritoneal function calculated by personal dialysis capacity in a patient after long-term continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 97-102.	0.1	1
115	Gastric angiodysplasia in patients undergoing maintenance dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 136-42.	0.1	8
116	Once-weekly hemodialysis helps continuous ambulatory peritoneal dialysis patients who have insufficient solute removal. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 143-7.	0.1	2
117	Peritoneal dialysis versus hemodialysis: a five-year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 148-54.	0.1	8
118	Fructosamine Assay Using Albumin Extracted from Serum Biological and Pharmaceutical Bulletin, 2002, 25, 1121-1124.	1.4	15
119	Systemic Capillary Leak Syndrome Internal Medicine, 2002, 41, 953-956.	0.7	32
120	Interstitial Fibroblast-Like Cells Express Renin-Angiotensin System Components in a Fibrosing Murine Kidney. American Journal of Pathology, 2002, 160, 765-772.	3.8	29
121	TGF-Î <sup>2</sup> 1 and HGF coordinately facilitate collagen turnover in subepithelial mesenchyme. Biochemical and Biophysical Research Communications, 2002, 297, 255-260.	2.1	18
122	Selection of the Dose of Angiotensin Converting Enzyme Inhibitor for Patients with Diabetic Nephropathy Depends on the Presence or Absence of Left Ventricular Hypertorphy Hypertension Research, 2002, 25, 865-873.	2.7	11
123	Intensive Blood Pressure Reduction Is Beneficial in Patients with Impaired Cardiac Function Coexisting with Chronic Renal Insufficiency. Hypertension Research, 2002, 25, 41-48.	2.7	2
124	Transient receptor potential channels in rat renal microcirculation: Actions of angiotensin II. Kidney International, 2002, 62, 558-565.	5.2	40
125	The Effects of Antihypertensive Agents on the Survival Rate of Polycystic Kideney Disease in Han: SPRD Rats Hypertension Research, 2002, 25, 939-943.	2.7	5
126	An increase in serum phosphate by sodium arginate Nihon Toseki Igakkai Zasshi, 2002, 35, 1583-1585.	0.1	0

#	Article	IF	Citations
127	Cilnidipine Is As Effective As Benazepril for Control of Blood Pressure and Proteinuria in Hypertensive Patients with Benign Nephrosclerosis Hypertension Research, 2001, 24, 377-383.	2.7	44
128	Comparison of the Effects of an ACE Inhibitor and .ALPHABETA. Blocker on the Progression of Renal Failure with Left Ventricular Hypertrophy: Preliminary Report Hypertension Research, 2001, 24, 153-158.	2.7	17
129	Renal fibroblast-like cells in Goodpasture syndrome rats. Kidney International, 2001, 60, 597-606.	5.2	25
130	Improved Outcome Prediction for Patients with Multiple Organ Failure Undergoing Continuous Hemodiafiltration. Therapeutic Apheresis and Dialysis, 2001, 5, 31-35.	0.9	4
131	Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis. Blood Purification, 2001, 19, 361-369.	1.8	106
132	Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on highâ€flux haemodialysis and human recombinant erythropoietin. Nephrology Dialysis Transplantation, 2000, 15, 1410-1413.	0.7	34
133	Role of T lymphocytes in renal disease in HIV-transgenic mice. American Journal of Kidney Diseases, 2000, 35, 408-417.	1.9	7
134	INFLUENCE OF THE TIMING OF INITIATING ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE RATS WITH RENAL FAILURE. Clinical and Experimental Hypertension, 2000, 22, 521-529.	1.3	1
135	Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and IL-6 production in human mesangial cells. Kidney International, 1998, 54, 71-79.	5.2	14
136	Role of chloride channels in afferent arteriolar constriction. Kidney International, 1996, 50, 864-872.	5.2	49
137	Effects of Novel, Nonpeptide Vasopressin Antagonists on Progressive Nephrosclerosis in Rats. Journal of Cardiovascular Pharmacology, 1995, 25, 847-852.	1.9	16
138	Renal Responses to Angiotensin Receptor Antagonist and Angiotensin-Converting Enzyme Inhibitor in Partially Nephrectomized Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1995, 26, 564-569.	1.9	22
139	The Effects of Chronic, and Selective Vasopressin Receptor Blockade in Spontaneously Hypertensive Rats. International Heart Journal, 1995, 36, 538-538.	0.6	0
140	Interleukin-4 Expression in Mesangial Proliferative Glomerulonephritis. American Journal of Kidney Diseases, 1994, 23, 242-246.	1.9	30
141	Acquired Idiopathic Pure Red Cell Aplasia in a Hemodialyzed Patient with Inactive Systemic Lupus Erythematosus Internal Medicine, 1994, 33, 492-495.	0.7	6
142	Renal Protective Effects of Amlodipine on Partially Nephrectomized Spontaneously Hypertensive Rats Fed a High-Salt Diet. Journal of Cardiovascular Pharmacology, 1994, 23, 480-484.	1.9	4
143	Evidence for Abnormalities in Parasympathetic Nerve-Mediated Reflexes in Borderline Hypertension Hypertension Research, 1993, 16, 185-190.	2.7	4
144	Hypertension as Three Systematic Dysregulations of Na+ Homeostasis in Terrestrial Mammal, and Salt in Gut Might Cause Brain Inflammation. , 0, , .		1